doi: 10.1038/ncb2784 3 AhmedC.GreveH
Individual results may vary A plan that works for you Insurance Were in network with Medicare and most PPO plans, including Aetna, Blue Shield, United, and more Co-pays only Monthly video visits with weight loss expert Affordable access to GLP-1 medications Unlimited support via chat and our app Monthly dietitian visits Smart scale to automatically track your weight* Self-Pay Telehealth and prescriptions for an affordable price $99/mo $49/mo Save $50 off the first month Monthly video visits with weight loss expert Affordable access to GLP-1 medications Unlimited support via chat and our app On sale *Members receive a cellular-enabled scale to use throughout their journey with us
Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention
This initiative yielded considerable success, marking an important step toward improving public health
It can cause pain, difficulty swallowing, and mouth sores
